 ErbB Receptors
"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.
| Descriptor ID |
D066246
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
|
| Concept/Terms |
ErbB Receptors- ErbB Receptors
- Receptors, ErbB
- Receptors, Epidermal Growth Factor-Urogastrone
- Receptors, Epidermal Growth Factor Urogastrone
- Receptors, Epidermal Growth Factor
- EGF Receptors
- Receptors, EGF
- Epidermal Growth Factor Receptor Family Proteins
- HER Family Receptors
- Family Receptors, HER
- Receptors, HER Family
- Erb-b2 Receptor Tyrosine Kinases
- Erb b2 Receptor Tyrosine Kinases
|
Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".
Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".
This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 4 | 7 | | 1996 | 2 | 2 | 4 | | 1997 | 2 | 2 | 4 | | 1998 | 1 | 1 | 2 | | 1999 | 3 | 0 | 3 | | 2000 | 2 | 2 | 4 | | 2001 | 2 | 1 | 3 | | 2002 | 7 | 2 | 9 | | 2003 | 6 | 3 | 9 | | 2004 | 6 | 3 | 9 | | 2005 | 8 | 4 | 12 | | 2006 | 21 | 9 | 30 | | 2007 | 12 | 3 | 15 | | 2008 | 13 | 5 | 18 | | 2009 | 9 | 5 | 14 | | 2010 | 13 | 10 | 23 | | 2011 | 6 | 4 | 10 | | 2012 | 11 | 7 | 18 | | 2013 | 9 | 9 | 18 | | 2014 | 5 | 10 | 15 | | 2015 | 7 | 7 | 14 | | 2016 | 12 | 13 | 25 | | 2017 | 14 | 8 | 22 | | 2018 | 3 | 16 | 19 | | 2019 | 3 | 15 | 18 | | 2020 | 3 | 8 | 11 | | 2021 | 1 | 6 | 7 | | 2022 | 0 | 14 | 14 | | 2023 | 0 | 10 | 10 | | 2024 | 5 | 4 | 9 | | 2025 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Girard N, Xu Q, Camidge DR, Baijal S, Ng S, Kamalakar R, Ratajczak C, Alhasani H, Crawford S, Karve S, Lu S. Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101. Oncologist. 2025 May 08; 30(5).
-
Xu Y, Yang JC, Zhao Y, Doucet L, Zhou J, Wang Y, Planchard D, Fan Y, Jin B, Han Z, Greillier L, Mazieres J, Sun M, Hu Y, Song X, Ding C, Wu L, Tang K, Liang L, Yao Y, Cheng Y, He Y, Ferreira BP, Ghiringhelli F, Felip E, Bosch-Barrera J, Liu A, Yu Y, Dong X, Gao J, Camidge DR, Nian W, Zhou C, Yang R, John T, Gao B, Bazhenova L, Nagasaka M, Wang J, Ren X, Xu F, Li W, Zhao D, Wang H, Sun S, Huang J, Zhu X, Zheng L, J?nne PA, Wang M. Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. Cell Rep Med. 2025 May 20; 6(5):102121.
-
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME. Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer. 2025 May; 203:108551.
-
Kratz JD, Rehman S, Johnson KA, Gillette AA, Sunil A, Favreau PF, Pasch CA, Miller D, Zarling LC, Yeung AH, Clipson L, Anderson SJ, Steimle AK, Sprackling CM, Lemmon KK, Abbott DE, Burkard ME, Bassetti MF, Eickhoff JC, Foley EF, Heise CP, Kimple RJ, Lawson EH, LoConte NK, Lubner SJ, Mulkerin DL, Matkowskyj KA, Sanger CB, Uboha NV, Mcilwain SJ, Ong IM, Carchman EH, Skala MC, Deming DA. Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity. Sci Rep. 2025 Apr 09; 15(1):12072.
-
Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025 May; 36(5):583-591.
-
Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, Liu G, Patel D, Liu SV, Montenegro GLB, Patil T, Nieva JJ, Herrmann A, Marrone KA, Lam VK, Schwartzman W, Dowell J, Villaruz LC, Miller KL, Weiss J, Sun F, Velcheti V, Camidge DR, Aggarwal C, Sun L, Marmarelis ME. Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer. Pharmacoepidemiol Drug Saf. 2024 12; 33(12):e70049.
-
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer. 2025 Jan; 199:108040.
-
Escoto A, Hecksel R, Parkinson C, Crane S, Atwell B, King S, Ortiz Chavez D, Jannuzi A, Sands B, Bitler BG, Fehniger TA, Paek AL, Padi M, Schroeder J. Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity. Oncogene. 2025 Feb; 44(5):288-295.
-
Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC). J Clin Oncol. 2024 Oct 20; 42(30):3606-3617.
-
Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol. 2024 Sep 10; 42(26):3105-3114.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|